BCL-2-associated X protein (BAX) is a critical apoptotic regulator that can be transformed from a cytosolic monomer into a lethal mitochondrial oligomer, yet drug strategies to modulate it are underdeveloped due to longstanding difficulties in conducting screens on this aggregation-prone protein. Here, we overcame prior challenges and performed an NMR-based fragment screen of full-length human BAX. We identified a compound that sensitizes BAX activation by binding to a pocket formed by the junction of the α3–α4 and α5–α6 hairpins. Biochemical and structural analyses revealed that the molecule sensitizes BAX by allosterically mobilizing the α1–α2 loop and BAX BH3 helix, two motifs implicated in the activation and oligomerization of BAX, respectively. By engaging a region of core hydrophobic interactions that otherwise preserve the BAX inactive state, the identified compound reveals fundamental mechanisms for conformational regulation of BAX and provides a new opportunity to reduce the apoptotic threshold for potential therapeutic benefit.
Subscribe to Journal
Get full journal access for 1 year
only $14.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Suzuki, M., Youle, R.J. & Tjandra, N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645–654 (2000).
Edlich, F. et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 145, 104–116 (2011).
Czabotar, P.E. et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152, 519–531 (2013).
Edwards, A.L. et al. Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem. Biol. 20, 888–902 (2013).
Gavathiotis, E., Reyna, D.E., Davis, M.L., Bird, G.H. & Walensky, L.D. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol. Cell 40, 481–492 (2010).
Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076–1081 (2008).
Barclay, L.A. et al. Inhibition of pro-apoptotic BAX by a noncanonical interaction mechanism. Mol. Cell 57, 873–886 (2015).
Ma, J. et al. Structural mechanism of Bax inhibition by cytomegalovirus protein vMIA. Proc. Natl. Acad. Sci. USA 109, 20901–20906 (2012).
Petros, A.M. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. USA 98, 3012–3017 (2001).
Walensky, L.D. & Gavathiotis, E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem. Sci. 36, 642–652 (2011).
Souers, A.J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997).
Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9, 390–397 (2013).
Tao, Z.F. et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5, 1088–1093 (2014).
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
Bruncko, M. et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J. Med. Chem. 58, 2180–2194 (2015).
Cohen, N.A. et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem. Biol. 19, 1175–1186 (2012).
Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477–482 (2016).
Leverson, J.D. et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 6, e1590 (2015).
Pelz, N.F. et al. Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods. J. Med. Chem. 59, 2054–2066 (2016).
Stewart, M.L., Fire, E., Keating, A.E. & Walensky, L.D. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol. 6, 595–601 (2010).
Huhn, A.J., Guerra, R.M., Harvey, E.P., Bird, G.H. & Walensky, L.D. Selective covalent targeting of anti-apoptotic BFL-1 by cysteine-reactive stapled peptide inhibitors. Cell. Chem. Biol. 23, 1123–1134 (2016).
Gavathiotis, E., Reyna, D.E., Bellairs, J.A., Leshchiner, E.S. & Walensky, L.D. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 8, 639–645 (2012).
Brahmbhatt, H., Uehling, D., Al-Awar, R., Leber, B. & Andrews, D. Small molecules reveal an alternative mechanism of Bax activation. Biochem. J. 473, 1073–1083 (2016).
Xin, M. et al. Small-molecule Bax agonists for cancer therapy. Nat. Commun. 5, 4935 (2014).
Zhao, G. et al. Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol. Cell. Biol. 34, 1198–1207 (2014).
Wang, K., Gross, A., Waksman, G. & Korsmeyer, S.J. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol. Cell. Biol. 18, 6083–6089 (1998).
Scott, D.E., Coyne, A.G., Hudson, S.A. & Abell, C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51, 4990–5003 (2012).
Mayer, M. & Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 38, 1784–1788 (1999).
Stockman, B.J. & Dalvit, C. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc. 41, 187–231 (2002).
Tan, C. et al. Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2. J. Biol. Chem. 281, 14764–14775 (2006).
Wei, M.C. et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14, 2060–2071 (2000).
Pagliari, L.J. et al. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc. Natl. Acad. Sci. USA 102, 17975–17980 (2005).
Sarosiek, K.A. et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol. Cell 51, 751–765 (2013).
McGovern, S.L., Helfand, B.T., Feng, B. & Shoichet, B.K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46, 4265–4272 (2003).
Irwin, J.J. et al. An aggregation advisor for ligand discovery. J. Med. Chem. 58, 7076–7087 (2015).
Julien, O. et al. Unraveling the mechanism of cell death induced by chemical fibrils. Nat. Chem. Biol. 10, 969–976 (2014).
Arnoult, D. et al. Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proc. Natl. Acad. Sci. USA 101, 7988–7993 (2004).
Poncet, D. et al. An anti-apoptotic viral protein that recruits Bax to mitochondria. J. Biol. Chem. 279, 22605–22614 (2004).
Kozakov, D. et al. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat. Protoc. 10, 733–755 (2015).
Engen, J.R. Analysis of protein conformation and dynamics by hydrogen/deuterium exchange MS. Anal. Chem. 81, 7870–7875 (2009).
Laiken, S.L., Printz, M.P. & Craig, L.C. Tritium-hydrogen exchange studies of protein models. I. Gramicidin S-A. Biochemistry 8, 519–526 (1969).
Printz, M.P., Williams, H.P. & Craig, L.C. Evidence for the presence of hydrogen-bonded secondary structure in angiotensin II in aqueous solution. Proc. Natl. Acad. Sci. USA 69, 378–382 (1972).
Shi, X.E. et al. Hydrogen exchange-mass spectrometry measures stapled peptide conformational dynamics and predicts pharmacokinetic properties. Anal. Chem. 85, 11185–11188 (2013).
Hsu, Y.T. & Youle, R.J. Nonionic detergents induce dimerization among members of the Bcl-2 family. J. Biol. Chem. 272, 13829–13834 (1997).
Goping, I.S. et al. Regulated targeting of BAX to mitochondria. J. Cell Biol. 143, 207–215 (1998).
Follis, A.V. et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat. Chem. Biol. 9, 163–168 (2013).
Lee, S. et al. Allosteric inhibition of antiapoptotic MCL-1. Nat. Struct. Mol. Biol. 23, 600–607 (2016).
Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).
Leshchiner, E.S., Braun, C.R., Bird, G.H. & Walensky, L.D. Direct activation of full-length proapoptotic BAK. Proc. Natl. Acad. Sci. USA 110, E986–E995 (2013).
Bird, G.H., Crannell, W.C. & Walensky, L.D. Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic targeting. Curr. Protoc. Chem. Biol. 3, 99–117 (2011).
Pitter, K., Bernal, F., Labelle, J. & Walensky, L.D. Dissection of the BCL-2 family signaling network with stabilized alpha-helices of BCL-2 domains. Methods Enzymol. 446, 387–408 (2008).
Hajduk, P.J., Olejniczak, E.T. & Fesik, S.W. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119, 12257–12261 (1997).
Hwang, T.-L. & Shaka, A.J. Water suppression that works. Excitation sculpting using arbitrary waveforms and pulsed field gradients. J. Magn. Reson. A 112, 275–279 (1995).
Vranken, W.F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
Williamson, M.P. Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 73, 1–16 (2013).
Grant, B.J., Rodrigues, A.P., ElSawy, K.M., McCammon, J.A. & Caves, L.S. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22, 2695–2696 (2006).
Skjærven, L., Yao, X.Q., Scarabelli, G. & Grant, B.J. Integrating protein structural dynamics and evolutionary analysis with Bio3D. BMC Bioinformatics 15, 399 (2014).
Yao, X.Q., Skjærven, L. & Grant, B.J. Rapid characterization of allosteric networks with ensemble normal mode analysis. J. Phys. Chem. B 120, 8276–8288 (2016).
Llambi, F. et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 44, 517–531 (2011).
We thank E. Smith for graphics support; C. Sheahan for operational assistance with the NMR screen; M. Godes for assistance with mitochondrial preparation; G. Bird and T. Oo for peptide production; M. Ericsson and Z. Hauseman for technical assistance with electron microscopy; H.-S. Seo and S. Dhe-Paganon for ITC experiments; and D. Andrews (Sunnybrook Research Institute) and K. Sarosiek (Harvard T.H. Chan School of Public Health) for providing BIML plasmid and protein, respectively. This research was supported by NIH grant 1R35CA197583, a Leukemia and Lymphoma Society (LLS) Scholar Award, the Todd J. Schwartz Memorial Fund, the Wolpoff Family Foundation, and a grant from the William Lawrence and Blanche Hughes Foundation to L.D.W.; NIH grant R01GM101135 to J.R.E. and a research collaboration with the Waters Corporation (J.R.E.); NIH grant F31CA189651 to J.R.P.; an Alexander von Humboldt Foundation Feodor Lynen Fellowship to F.W.; and NIH training grant T32GM007753 to J.L.
The authors declare no competing financial interests.
Supplementary Results, Supplementary Tables 1–4 and Supplementary Figures 1–12 (PDF 15465 kb)
Molecular dynamics simulation of BAX (PDB ID 1F16) in solution (100 ns)
The D1–D2 loop (yellow; top of screen) shows relatively little motion and remains fixed over the D1/D6 (orange/cyan) trigger site at the N-terminal face of BAX ("closed" conformation). (MOV 7329 kb)
Compared to unliganded BAX, there is increased flexibility and intermittent release of the D1–D2 loop (yellow; top of screen) from the D1/D6 (orange/cyan) trigger site, where BH3 interaction and displacement of the loop to the "open" conformation represents the initiating structural change of direct BAX activation. BIF-44 (stick representation) remains stablypositioned at an allosteric binding site formed by the junction of the D3/D4 and D5/D6 hairpins, distant from the D1–D2 loop. (MOV 6394 kb)
About this article
Cite this article
Pritz, J., Wachter, F., Lee, S. et al. Allosteric sensitization of proapoptotic BAX. Nat Chem Biol 13, 961–967 (2017). https://doi.org/10.1038/nchembio.2433
Insights into Mcl-1 Conformational States and Allosteric Inhibition Mechanism from Molecular Dynamics Simulations, Enhanced Sampling, and Pocket Crosstalk Analysis
Journal of Chemical Information and Modeling (2020)
Cold Spring Harbor Perspectives in Biology (2020)
Journal of Medicinal Chemistry (2020)
Humanin induces conformational changes in the apoptosis regulator BAX and sequesters it into fibers, preventing mitochondrial outer-membrane permeabilization
Journal of Biological Chemistry (2019)
Resveratrol protects cardiomyocytes against anoxia/reoxygenation via dephosphorylation of VDAC1 by Akt-GSK3 β pathway
European Journal of Pharmacology (2019)